scholarly article | Q13442814 |
P50 | author | Philip B. Mitchell | Q37393406 |
P2093 | author name string | D Birkett | |
P McManus | |||
J Dudley | |||
A Mant | |||
P2860 | cites work | Fatal toxicity of antidepressant drugs in overdose | Q24533406 |
Antidepressant treatment of the depressed patient with insomnia. | Q33710732 | ||
Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia | Q35803323 | ||
A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression | Q41180795 | ||
Drug interactions of clinical significance with selective serotonin reuptake inhibitors | Q41682186 | ||
Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs | Q46182804 | ||
Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. | Q51985448 | ||
Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. | Q54261629 | ||
Combination treatment of depression | Q70566314 | ||
SSRIs and tricyclic antidepressants | Q70610761 | ||
Starting SSRI antidepressant therapy: its effect on tricyclic antidepressant and benzodiazepine prescribing | Q71041072 | ||
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association | Q73682867 | ||
Liability in prescribing choice: the example of the antidepressants | Q77120667 | ||
Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression | Q77764403 | ||
Drugs for depression and anxiety | Q77809314 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Australia | Q408 |
P304 | page(s) | 93-98 | |
P577 | publication date | 2001-01-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? | |
P478 | volume | 51 |
Q38687957 | Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. |
Q46197689 | The Risk of Hip Fracture Due to Mirtazapine Exposure When Switching Antidepressants or Using Other Antidepressants as Add-On Therapy |
Q35070953 | The strategy of combining antidepressants in the treatment of major depression: clinical experience in spanish outpatients |
Q24564967 | Tricyclic antidepressant pharmacology and therapeutic drug interactions updated |
Q33364541 | Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data |
Search more.